Category - Markets

Rodman & Renshaw analyst Raghuram Selvaraju has assumed coverage of NephroGenex (NASDAQ:NRX) with a “neutral” rating and without a price target. The stock was quoted at 40 cents Friday afternoon. The board of...

Canaccord Genuity has launched coverage of CryoLife (NYSE:CRY) with a “buy” rating and $14 yearend price target. The stock closed at $11 on Tuesday. “We recommend small-cap GARP (growth at a reasonable price) investors...

GMP Securities has initiated coverage of Profound Medical (TSX-V:PRN) with a “speculative buy” rating and price target of $2. The stock closed at $1.50 on Monday. The company is focused on developing and commercializing...

BTIG Research has launched coverage of Senseonics Holdings (NYSE MKT:SENS) with a “buy” rating and 12-month price target of $4.50. The stock closed at $2.97 on Monday. “This may be a better way to monitor glucose if...

H.C. Wainwright has initiated coverage of Tobira Therapeutics (NASDAQ:TBRA) with a “buy” rating and $22 price target. The stock closed at $7.30 on Friday. Tobira is focused on the development of a sole drug candidate...

H.C. Wainwright has initiated coverage of BioPharmX (NYSE MKT:BPMX) with a “buy” rating and $3 price target. The stock closed at 99 cents on Wednesday. BioPharmX’s lead product is Violet for the treatment of fibrocystic...

Canaccord Genuity has downgraded AngioDynamics (NASDAQ:ANGO) to “hold” from “buy” and reduced its price target to $13 from $14.50, following the abrupt departure of CEO, Joe DeVivo, “which we think will heighten...

Stifel has upgraded Exelixis (NASDAQ:EXEL) to “buy” from “hold” with a price target of $7. The stock closed at $4.05 on Friday. Exelixis is developing small molecule therapies for the treatment of cancer and is focusing...

BTIG has launched coverage of OraSure Technologies (NASDAQ:OSUR) with a “buy” rating and price target of $8. The stock closed at $6.19 on Friday. “A profitable small-cap diagnostics company is a rare find,” writes...

H.C. Wainwright has launched coverage of Kiadis Pharma NV (NXT AM:KDS) of Amsterdam with a “buy” rating and price target of €15. The stock closed at €10 on Friday. “We view Kiadis as an innovator in hematopoietic stem...